## Xiaoming Dai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2237216/publications.pdf

Version: 2024-02-01

10	593	1040056	1372567
papers	citations	h-index	g-index
10	10	10	499
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy. Seminars in Cancer Biology, 2022, 85, 246-252.	9.6	38
2	DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway. Science Signaling, 2022, 15, eabh2290.	3.6	16
3	S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions. Nature Communications, 2022, 13, 1548.	12.8	19
4	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular Cell, 2021, 81, 2317-2331.e6.	9.7	97
5	Copper Promotes Tumorigenesis by Activating the PDK1â€AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner. Advanced Science, 2021, 8, e2004303.	11.2	66
6	Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology, 2020, 22, 1064-1075.	10.3	182
7	LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nature Cell Biology, 2020, 22, 246-256.	10.3	56
8	The diverse roles of SPOP in prostate cancer and kidney cancer. Nature Reviews Urology, 2020, 17, 339-350.	3.8	62
9	DUB-independent regulation of pVHL by OTUD6B suppresses hepatocellular carcinoma. Protein and Cell, 2020, 11, 546-548.	11.0	4
10	RBR E3 ubiquitin ligases in tumorigenesis. Seminars in Cancer Biology, 2020, 67, 131-144.	9.6	53